GSK plc stock (GB0009252882): Mixed signals from recent earnings and pipeline updates

GSK plc reported its latest quarterly results and provided updates on its vaccine and pharmaceutical pipeline, with mixed reactions from investors.

GSK plc reported its first-quarter 2025 results on May 8, 2025, showing modest revenue growth but continued pressure on profitability, according to GSK investor relations as of May 8, 2025. The company posted total revenue of £7.1 billion, up 1% year over year at constant exchange rates, driven by growth in vaccines and consumer healthcare, while pharmaceuticals declined slightly. Adjusted operating profit fell 11% to £1.8 billion, reflecting higher research and development spending and ongoing restructuring costs.

The London-based healthcare group highlighted progress in its respiratory and HIV portfolios, with Trelegy Ellipta and Dovato contributing solid sales, while its Shingrix vaccine continued to be a key growth driver. However, GSK also noted that patent expiries and generic competition remain headwinds for several legacy products. The company maintained its 2025 financial guidance, including expectations for low single-digit revenue growth and adjusted operating profit margin in the mid?30% range, according to GSK investor relations as of May 8, 2025.

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: GSK plc
• Sector/industry: Pharmaceuticals and healthcare
• Headquarters/country: London, United Kingdom
• Core markets: United States, Europe, emerging markets
• Key revenue drivers: Vaccines (Shingrix), respiratory medicines, HIV treatments, consumer healthcare
• Home exchange/listing venue: London Stock Exchange (ticker: GSK); also listed on the New York Stock Exchange as ADRs
• Trading currency: GBP (LSE), USD (NYSE ADRs)

GSK plc: core business model

GSK plc operates as a global research-based pharmaceutical and consumer healthcare company, with a diversified portfolio spanning prescription medicines, vaccines and over-the-counter consumer products. The company’s strategy centers on leveraging its R&D capabilities in respiratory, HIV, oncology and vaccines, while maintaining a broad consumer health business that includes brands such as Sensodyne, Panadol and Advil. This dual focus allows GSK to balance higher-margin, patent-protected pharmaceuticals with more stable, volume-driven consumer products.

The company’s pharmaceutical segment includes established brands like Trelegy Ellipta for chronic obstructive pulmonary disease and asthma, as well as Dovato and other HIV therapies that benefit from long treatment durations and relatively high pricing power. Vaccines remain a structural growth pillar, with Shingrix for shingles prevention and other immunization products contributing a growing share of group revenue. Consumer healthcare, while less profitable than pharmaceuticals, provides geographic diversification and steady cash flow, which GSK has used to fund R&D and strategic acquisitions.

Main revenue and product drivers for GSK plc

Within GSK’s pharmaceutical business, respiratory and HIV therapies are the largest revenue contributors. Trelegy Ellipta, a once-daily triple-combination inhaler, continues to gain market share in asthma and COPD, supported by clinical data and payer coverage in key markets such as the United States and Europe. HIV treatments, including Dovato and other integrase inhibitor?based regimens, benefit from a shift toward simpler, once?daily regimens and long-term treatment adherence, which underpins recurring demand.

The vaccine portfolio is another critical growth engine, with Shingrix remaining a standout performer. The shingles vaccine has been widely adopted in national immunization programs, particularly among older adults, and GSK has expanded indications and geographic approvals over recent years. The company also markets vaccines for pneumococcal disease, meningitis and other infectious diseases, which contribute to a more diversified immunization franchise. Consumer healthcare products, while facing pricing pressure and competition from generics and private labels, still generate meaningful revenue and margins, especially in oral health and pain relief categories.

Why GSK plc matters for US investors

For US investors, GSK represents exposure to a large, diversified healthcare company with significant operations in the United States, one of the world’s largest pharmaceutical markets. The company’s respiratory and HIV products are widely prescribed in the US, and its vaccines are integrated into national and private immunization programs. GSK’s ADR listing on the New York Stock Exchange provides direct access for American investors, while the London listing offers exposure to sterling-denominated cash flows and UK market dynamics.

US investors may also view GSK as a relatively defensive healthcare holding, given the recurring nature of many of its products and the long development cycles that create barriers to entry. However, the stock is not without risk, including exposure to patent expiries, pricing pressure from payers and regulators, and the inherent uncertainty of drug development. These factors make GSK a candidate for investors seeking diversified healthcare exposure rather than pure growth or speculative biotech exposure.

Conclusion

GSK plc continues to navigate a complex healthcare landscape marked by patent expiries, generic competition and evolving regulatory and payer environments. Recent quarterly results show modest revenue growth but declining profitability, reflecting higher R&D investment and restructuring costs. The company’s diversified portfolio of pharmaceuticals, vaccines and consumer healthcare provides some resilience, yet investors must weigh this against ongoing margin pressure and pipeline risk.

For US investors, GSK offers exposure to a global healthcare leader with meaningful operations in the United States and a broad product base across respiratory, HIV, vaccines and consumer health. The stock may appeal to those seeking diversified healthcare exposure rather than high-beta growth, but it also carries typical pharmaceutical industry risks such as clinical trial outcomes, regulatory decisions and pricing scrutiny. As with any equity investment, investors should consider their risk tolerance, time horizon and portfolio diversification before making decisions.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.